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d ARID1A inactivation enhanced growth suppression induced
by HDAC2 inhibition
d HDAC2 interacts with EZH2 in an ARID1A status-dependent
manner
d HDAC2 functions as a co-repressor of EZH2 to promote
apoptosis
d SAHA improved the survival of mice bearing ARID1A-
mutated cancer
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In Brief
Fukumoto et al. show that ARID1A
mutation confers sensitivity to pan-HDAC
inhibitors such as SAHA in ovarian
cancers. This correlated with enhanced
growth suppression induced by the
inhibition of HDAC2 activity in ARID1A-
mutated cells. These findings provided
preclinical rationales for repurposing
FDA-approved pan-HDAC inhibitors for
treating ARID1A-mutated cancers.
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